Page last updated: 2024-11-13
fumonisin b4
Description
fumonisin B4: from Fusarium moniliforme; has cancer-promoting activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
fumonisin B4 : A fumonisin that is fumonisin B2 that is lacking hydroxy group located gamma- to the amino substituent. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
Synonyms (7)
Synonym |
fumonisin b4 |
LMSP01080025 |
(2r,2'r)-2,2'-{[(5r,6r,7s,9s,18s,19s)-19-amino-18-hydroxy-5,9-dimethylicosane-6,7-diyl]bis[oxy(2-oxoethane-2,1-diyl)]}disuccinic acid |
136379-60-7 |
CHEBI:133832 |
(2r)-2-[2-[(5r,6r,7s,9s,18s,19s)-19-amino-6-[(3r)-3,4-dicarboxybutanoyl]oxy-18-hydroxy-5,9-dimethylicosan-7-yl]oxy-2-oxoethyl]butanedioic acid |
Q63395740 |
Roles (1)
Role | Description |
Aspergillus metabolite | Any fungal metabolite produced during a metabolic reaction in the mould, Aspergillus. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (4)
Class | Description |
fumonisin | A family of toxins produced by several species of Fusarium moulds which occur mainly in maize. |
primary amino compound | A compound formally derived from ammonia by replacing one hydrogen atom by an organyl group. |
secondary alcohol | A secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it. |
diester | A diester is a compound containing two ester groups. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (16)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 8 (50.00) | 18.2507 |
2000's | 2 (12.50) | 29.6817 |
2010's | 5 (31.25) | 24.3611 |
2020's | 1 (6.25) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.67
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 11.67 (24.57) | Research Supply Index | 2.83 (2.92) | Research Growth Index | 4.51 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 2 (12.50%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 14 (87.50%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |